News

Zymenex enzyme moves into Phase 2b clinical trials in patients with the rare disease alpha-Mannosidosis

Zymenex enzyme gets US Orphan Drug Designation Approval from FDA

Positive clinical effect in Phase 2 trial in patients with the rare disease alpha-Mannosidosis

Zymenex enzyme gets EU Orphan Drug Designation Approval

Zymenex enzyme in Phase 2 clinical trials in patients with the rare disease alpha-Mannosidosis

Zymenex enzyme gets EU-millions for clinical trials in ALPHA-MAN project

Zymenex receives 500.000 dkr from the Advisory Council on Technology for a collaborative technology with Danish Technological Institute

Natural History Study of Krabbe Disease underway in the US

Zymenex acquires ACE Biosciences

Positive CNS/PNS effect data in Alpha-mannosidosis mouse model presented in Prague